OncoCyte Corporation
OCX
$2.73
$0.083.02%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -45.72% | -118.36% | 24.00% | 39.37% | 32.96% |
| Total Depreciation and Amortization | 11.47% | -6.90% | -49.64% | -60.49% | -65.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 80.83% | 488.51% | -20.71% | -26.79% | 24.29% |
| Change in Net Operating Assets | -242.86% | 66.73% | 78.00% | 85.15% | 51.02% |
| Cash from Operations | -20.61% | 11.20% | 30.71% | 50.24% | 53.55% |
| Capital Expenditure | -161.97% | -83.63% | 30.89% | 70.14% | 89.02% |
| Sale of Property, Plant, and Equipment | -98.87% | -98.87% | -100.00% | 87.80% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 126.75% | 126.75% | 126.75% |
| Cash from Investing | -291.11% | 45.06% | 89.17% | 103.51% | 110.02% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -235.96% | -71.79% | 20.32% | 86.42% | 91.70% |
| Issuance of Common Stock | 311.30% | 100.85% | 14.28% | 14.15% | -57.80% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -382.02% | -382.02% | -382.02% | -382.02% | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -434.43% | -320.37% | -69.79% | -26.00% | 11.41% |
| Cash from Financing | 301.07% | 67.64% | -21.08% | -15.76% | -66.20% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 508.85% | 93.41% | 42.97% | 70.47% | 27.52% |